XTX Topco Ltd Acquires New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

XTX Topco Ltd acquired a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 71,421 shares of the company’s stock, valued at approximately $315,000.

Other large investors have also bought and sold shares of the company. National Bank of Canada FI boosted its holdings in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock valued at $39,000 after acquiring an additional 2,151 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in shares of GoodRx during the fourth quarter valued at about $56,000. Total Wealth Planning & Management Inc. acquired a new stake in shares of GoodRx during the fourth quarter valued at about $68,000. Oxford Asset Management LLP acquired a new stake in shares of GoodRx during the fourth quarter valued at about $75,000. Finally, Gotham Asset Management LLC boosted its stake in shares of GoodRx by 31.0% during the fourth quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock valued at $82,000 after purchasing an additional 4,182 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Raymond James Financial downgraded GoodRx from a “strong-buy” rating to an “outperform” rating in a research note on Friday. Wells Fargo & Company dropped their price target on GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. UBS Group dropped their target price on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. Finally, The Goldman Sachs Group dropped their price objective on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.20.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is currently owned by insiders.

GoodRx Price Performance

GDRX opened at $3.47 on Monday. The company has a fifty day moving average price of $4.61 and a 200-day moving average price of $4.55. The firm has a market capitalization of $1.24 billion, a P/E ratio of 34.70, a price-to-earnings-growth ratio of 1.37 and a beta of 1.24. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx Holdings, Inc. has a one year low of $3.31 and a one year high of $8.80.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%. The company had revenue of $203.07 million during the quarter, compared to analysts’ expectations of $205.72 million. During the same period in the prior year, the firm earned $0.08 EPS. GoodRx’s quarterly revenue was up 1.2% on a year-over-year basis. Equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.